Sarcoma News and Research

RSS

Small molecule in pregnant women's urine apparently blocks cancer growth

University of Montreal scientists have identified a small molecule found in pregnant women's urine that apparently blocks the growth of several types of cancers, including AIDS-related Kaposi's sarcoma, which currently has no cure.

24 Jun 2014

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye.

20 Jun 2014

Researchers discover new class of tumor

This is the story of two perfectly harmless genes. By themselves, PAX3 and MAML3 don't cause any problems. However, when they combine during an abnormal but recurring chromosomal mismatch, they can be dangerous.

11 Jun 2014

Scientists unravel how herpesviruses fight against our immune system

How the virus does this was unknown until now. The scientists from the HZI research group "Viral Immune Modulation" under the leadership of Prof. Melanie Brinkmann have now been able to show that the virus is actively preventing activation of the innate immune system through Toll-like receptors.

9 Jun 2014

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

5 Jun 2014

Scientists reproduce chromosomal modifications in human cells that cause certain cancer

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and the Centro Nacional de Investigaciones Oncol-gicas (CNIO) have succeeded in reproducing, in human cells, the chromosomal translocations that cause two types of cancer: acute myeloid leukemia and Ewing's sarcoma.

5 Jun 2014

Researchers reproduce tumor chromosomal translocations in human cells

Scientists from the Spanish National Cancer Research Centre and the Spanish National Cardiovascular Research Centre have been able to reproduce, for the first time in human cells, chromosomal translocations associated with two types of cancer: acute myeloid leukaemia and Ewing's sarcoma.

4 Jun 2014

Researchers analysis adjuvant chemotherapy's impact on overall survival in patients with stage III STS

Fox Chase Cancer Center researchers have carried out the first retrospective analysis of adjuvant chemotherapy's impact on overall survival in patients with stage III soft tissue sarcomas (STS), adjusted for socioeconomic status and other variables.

31 May 2014

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.

28 May 2014

Socioeconomic status appears to influence type of cancer a person may develop

A new analysis has found that certain cancers are more concentrated in areas with high poverty, while other cancers arise more often in wealthy regions. Also, areas with higher poverty had lower cancer incidence and higher mortality than areas with lower poverty.

28 May 2014

New analysis finds that certain cancers are more concentrated in areas with high poverty

28 May 2014

EntreMed reports net loss of $1.5M in first quarter 2014

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three months ended March 31, 2014.

15 May 2014

Novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis

A novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis (PVNS), a rare neoplastic joint disorder, according to new phase I data from Memorial Sloan Kettering Cancer Center and other institutions highlighted to media today in advance of the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will take place from May 30 to June 3 in Chicago.

15 May 2014

Study: CD206-targeting Manocept platform may provide potential avenues to enhance diagnosis in Kaposi Sarcoma

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators from the University of California, San Francisco (UCSF) presented results at the 2014 American Association for Cancer Research (AACR) conference, April 5-9, 2014 in San Diego, CA, highlighting the potential utility of imaging agents derived from Navidea's Manocept™ platform in identifying affected tissues and lymph nodes in patients with Kaposi Sarcoma (KS).

10 Apr 2014

Moffitt Cancer Center initiates phase I clinical trial of cancer vaccine ID-G305

Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person's own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.

10 Apr 2014

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

31 Mar 2014

Rosa/KressWorks Foundation completes first milestone in development of Ewing's sarcoma PhysioPD Platform

Rosa & Co. LLC and the KressWorks Foundation are pleased to announce the completion of the Ewing's sarcoma PhysioMap®. Completion of the PhysioMap is the first milestone in the development of the Ewing's sarcoma PhysioPD Platform.

29 Mar 2014

Cytrx releases statement in response to two recent lawsuits

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today issued the following statement in response to two recent lawsuits filed in the name of CytRx shareholders:

27 Mar 2014

EORTC study does not support combination chemotherapy for soft tissue sarcoma

An EORTC study published in The Lancet Oncology does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the objective is to shrink the tumor.

27 Mar 2014

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.

26 Mar 2014

Sarcoma News and Research

Small molecule in pregnant women's urine apparently blocks cancer growth

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

Researchers discover new class of tumor

Scientists unravel how herpesviruses fight against our immune system

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Scientists reproduce chromosomal modifications in human cells that cause certain cancer

Researchers reproduce tumor chromosomal translocations in human cells

Researchers analysis adjuvant chemotherapy's impact on overall survival in patients with stage III STS

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

Socioeconomic status appears to influence type of cancer a person may develop

New analysis finds that certain cancers are more concentrated in areas with high poverty

EntreMed reports net loss of $1.5M in first quarter 2014

Novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis

Study: CD206-targeting Manocept platform may provide potential avenues to enhance diagnosis in Kaposi Sarcoma

Moffitt Cancer Center initiates phase I clinical trial of cancer vaccine ID-G305

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

Rosa/KressWorks Foundation completes first milestone in development of Ewing's sarcoma PhysioPD Platform

Cytrx releases statement in response to two recent lawsuits

EORTC study does not support combination chemotherapy for soft tissue sarcoma

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News